Policies and Procedures

The policies and procedures developed by The Biomarkers Consortium are intended to outline general principles to facilitate the use of data and technologies in expanded biomarker research and development efforts conducted by the consortium while ensuring compliance with relevant requirements of antitrust and other federal law.

The policies and procedures established by The Biomarkers Consortium include:

For more information about the policies and procedures of The Biomarkers Consortium, please contact us at biomarkers@fnih.org.

  • About Biomarkers

    Biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention. More

  • Join Us

    Become a Member
    Learn how you can join and support The Biomarkers Consortium.

    The Biomarkers Consortium embraces government, industry, patient advocacy groups, and non-profit organizations, each of which has a stake in the development of biomarker technology.

  • Latest News

    THE BIOMARKERS CONSORTIUM LAUNCHES I-SPY 2 BREAST CANCER CLINICAL TRIAL:  Click here to read the press release.

    March 17, 2010 -- Announcing the launch of the Biomarkers Consortium I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and moLecular analysis): An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy), which is taking place today from 9-10:30 a.m. ET at the National Press Club, Washington, DC.  Click here for more information.

    View the Web Cast

     

    Six awardees conducting data analysis to Develop Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults: Click here to read

    The Metabolic Disorders Steering Committee releases strategy for Mathematical Modeling in Atherosclerosis:  Details

    PRESS RELEASE:  The Biomarkers Consortium Completes First Project to Show That Adiponectin is a Predictive Biomarker for Type 2 Diabetes:  Click here to read

    RFP for Data Analysis to Develop Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults.  Due Date: September 8, 2009.  Click here to read.

     

    Available Now: The Biomarkers Consortium Report, Volume 1, Issue 1, May 2009. Click Here to Read

    The Metabolic Disorders Steering Committee Prioritized Areas of Unmet Need: As advertised in Volume 58, No. 4, April 2009 issue of Diabetes.  Click Here to read.

    Presentations Available from the Beta Cell Function Symposium. Click here for agenda.